Today in Science
SEE OTHER BRANDS

Fresh science news from the world

Today in Science: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.

Press releases published on May 13, 2025

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials

Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) …

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today …

Acronis Ecosystem Reaches 300 Technology Integrations, Drives New Opportunities for MSPs and ISVs

Acronis Ecosystem Reaches 300 Technology Integrations, Drives New Opportunities for MSPs and ISVs

SHAFFHAUSEN, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- Acronis, a global leader in cybersecurity and data protection, today announces a significant milestone in the Acronis Technology Ecosystem, which now includes nearly 300 integrations, reinforcing …

CareCloud Named “Top Healthcare IT Pick for 2025” by Maxim Group; AI Initiative Recognized as Key Growth Driver

CareCloud Named “Top Healthcare IT Pick for 2025” by Maxim Group; AI Initiative Recognized as Key Growth Driver

SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and generative AI solutions, today announced that Maxim Group, LLC (“Maxim Group”), a leading …

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and …

Mindera Health™ announces publication of randomized, prospective clinical utility study demonstrating improved psoriasis patient outcomes

Mindera Health™ announces publication of randomized, prospective clinical utility study demonstrating improved psoriasis patient outcomes

Vista, CA, May 13, 2025 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced positive results from the completion of a randomized, prospective clinical trial (MATCH) aimed at demonstrating the …

MicroAlgo Inc. Develops Blockchain-Based Traceable IP Rights Protection Algorithm

MicroAlgo Inc. Develops Blockchain-Based Traceable IP Rights Protection Algorithm

shenzhen, May 13, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. Develops Blockchain-Based Traceable IP Rights Protection Algorithm Shenzhen, May. 13, 2025/––MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ: MLGO), today announced the development of a …

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 13, 2025 (GLOBE …

Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies

Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies

In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs) In 15% or …

Bagel Market Size to worth USD 8.99 Billion by 2032, says Coherent Market Insights

Bagel Market Size to worth USD 8.99 Billion by 2032, says Coherent Market Insights

Burlingame, CA, May 13, 2025 (GLOBE NEWSWIRE) -- The global bagel market size was valued at USD 6.30 Billion in 2025 and is expected to reach USD 8.99 Billion by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032, as …

UPCX Becomes Official Associate Partner of Formula E Tokyo E-Prix 2025, Advancing Web3 and Sustainable Mobility

UPCX Becomes Official Associate Partner of Formula E Tokyo E-Prix 2025, Advancing Web3 and Sustainable Mobility

Singapore, May 13, 2025 (GLOBE NEWSWIRE) -- UPCX, a leading blockchain-based open-source payment platform, is thrilled to announce its official sponsorship of the ABB FIA Formula E World Championship Tokyo E-Prix 2025 as an Associate Partner. This landmark …

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a …

Consumer expert Lady Janey claims businesses could lose out with overreliance on AI in customer service

Consumer expert Lady Janey claims businesses could lose out with overreliance on AI in customer service

TEWKESBURY, United Kingdom, May 13, 2025 (GLOBE NEWSWIRE) -- A consumer expert has said businesses must put customers at the forefront of any plans to expand the use of AI - or risk losing trade. Jane Hawkes, from the Lady Janey blog, said UK brands “risk …

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of …

Intuitive Machines Reports First Quarter 2025 Financial Results

Intuitive Machines Reports First Quarter 2025 Financial Results

HOUSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), a leading space technology and infrastructure services company, today announced its financial results for the first quarter ended …

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“ …

Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City

Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City

MONTREAL, May 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a …

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is …

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service